Laurus Labs is currently trading at Rs. 359.00, up by 6.55 points or 1.86% from its previous closing of Rs. 352.45 on the BSE.
The scrip opened at Rs. 371.00 and has touched a high and low of Rs. 371.00 and Rs. 351.00 respectively.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 548.55 on 14-Feb-2018 and a 52 week low of Rs. 330.30 on 26-Oct-2018.
Last one week high and low of the scrip stood at Rs. 375.00 and Rs. 351.00 respectively. The current market cap of the company is Rs. 3751.36 crore.
The promoters holding in the company stood at 33.50%, while Institutions and Non-Institutions held 46.38% and 20.13% respectively.
Laurus Labs has received tentative approval from United States Food and Drug Administration (USFDA) under PEPFAR for Tenofovir / Lamivudine / Dolutegravir (TLD) 300/300/50mg fixed dose combination (FDC).
The TLD product will be available in the Generic form in low and middle income countries (LMIC). TLD is the preferred treatment recommended by US department of Health and Human Services Panel and also WHO has recommended TLD as one of the preferred first line regimen for the treatment of people living with HIV.
The company expects to commercialise this important medicine in the access markets and the product will be manufactured from the company's Unit 2 located at APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh.
Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1861.70 |
Dr. Reddys Lab | 1391.35 |
Cipla | 1506.35 |
Lupin | 2227.60 |
Zydus Lifesciences | 972.45 |
View more.. |